Thelansis

Postherpetic Neuralgia (PHN) Market Outlook Thelansis’s “Postherpetic Neuralgia (PHN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Postherpetic Neuralgia (PHN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the ...

  Postherpetic Neuralgia (PHN) Market Outlook Thelansis’s “Postherpetic Neuralgia (PHN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Postherpetic Neuralgia (PHN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Postherpetic Neuralgia (PHN) Overview Postherpetic neuralgia (PHN) is the most frequent long-term consequence of the reactivation of the varicella-zoster virus (VZV), also known as human herpesvirus-3 (HHV-3). VZV is the virus that causes the pediatric illness varicella, or chickenpox. The virus remains dormant in nerve cells after a chickenpox infection and, if reactivated, it causes shingles, or herpes zoster. It is ...

  Postherpetic neuralgia (PHN) is often called human herpesvirus-3 (HHV-3). It is the most frequent long-term consequence of reactivation of varicella-zoster virus (VZV). It is called shingles or herpes zoster when the dormant VZV reactivates. The pediatric illness varicella, also called chickenpox, is caused by VZV. It is unclear exactly what physiologically distinguishes postherpetic neuralgia from a self-limited zoster epidemic. Histological analyses of pertinent peripheral and central nerve tissue from PHN patients show atrophy of the dorsal horn in some cases and myelin and axon deficit in others. For postherpetic neuralgia, three primary therapeutic modalities might be taken into consideration. The first is preventive, which aims to identify and immunize populations at risk of acquiring HZ. The second is prompt diagnosis and intervention. Thelansis’s “Postherpetic Neuralgia (PHN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2...